Fabric Genomics Announces Expanded Oncology Solution, Extending Somatic Cancer Analysis to Clinical Labs

Share This.....Share on LinkedInTweet about this on TwitterShare on FacebookShare on Google+Email this to someone

Solution enables clinical labs that perform cancer NGS testing to quickly convert genomic insights to targeted therapies

SALT LAKE CITY–(BUSINESS WIRE)–This week, at the Association for Molecular Pathology (AMP) Annual Meeting, Fabric Genomics will announce its expanded somatic cancer solution which provides seamless genomic analysis and clinical reporting to clinical labs. The offering enables therapy matching for cancer patients, giving clinicians targeted treatment choices for cancer patients. Now clinical labs have one integrated platform for the interpretation of somatic cancer panels, hereditary panels, and whole genomes.

“The Fabric Genomics’ somatic cancer solution is a natural extension of our already established platform for hereditary diseases and furthers Fabric Genomics’ goal to improve cancer clinical care through genomic medicine,” said Paul R. Billings, M.D., Ph.D., Chief Medical Officer at Fabric Genomics. “Being able to quickly interpret somatic cancer variants from a tumor or liquid biopsy, and then match those to targeted therapies, is of critical importance to successfully treating cancer patients. NGS-based cancer panels are increasingly being used by clinicians to match cancer patients with FDA-approved drugs and experimental therapies, and improve patient outcomes.”

Fabric Genomics’ cancer solutions provide a next generation sequencing workflow for both inherited cancer risk and somatic cancer testing, including solid-tumor, hematology, and liquid biopsy samples. The company’s expanded somatic cancer capabilities now include variant calling, annotation from cancer-specific databases, clinical curation from multiple providers, and the ability to quickly create physician-ready clinical reports. Somatic variants can be scored and reported in accordance with the 2017 AMP scoring guidelines, which were created to provide a standardized format for presenting somatic variants in a clinical report. The clinical reports generated with Fabric Genomics’ somatic cancer offering are already being used in tumor board meetings at clinical sites. The expanded somatic cancer offering adds to Fabric Genomics’ already established analysis platform for hereditary diseases, as demonstrated by partnerships with Genomics England, Rady Children’s Institute for Genomic Medicine, and The Utah Genome Project.

“Fabric Genomics is a leader in genomic analysis of hereditary diseases, focusing on helping critically-ill children in the NICU/PICU, children with rare diseases, and patients who carry a hereditary mutation that puts them at risk for diseases such as cancer, cardiovascular disease, Alzheimer’s Disease, and more,” said Dr. Joshua Schiffman, M.D., Professor of Pediatrics at the University of Utah, Medical Director of the Family Cancer Assessment Clinic at Huntsman Cancer Institute, and Fabric Genomics’ Scientific Advisory Board Member. “We need the highest scientific rigor and clinical validation to drive the adoption of clinical genomics in cancer risk and surveillance.”

At the AMP Meeting:

-Corporate Workshop Talk presented by Joshua Schiffman, M.D., Wednesday, November 15th, at 8 A.M., Room 255A

-Booth #827, November 16th-18th

-Scientific Poster I-01, Saturday, November 18th, 9:45-10:45 A.M.

About Fabric Genomics

By accelerating access to insights related to the cause of genetic diseases, Fabric Genomics™ is leading the way in precision healthcare. Fabric Genomics is a global company offering end-to-end genomic data analysis, annotation, curation, classification, and reporting solutions to clinical labs, hospital labs, country sequencing programs, and life science companies. Fabric Genomics’ analytic capabilities cover the complete NGS workflow, between the sequencer and the clinical report. Our software is optimized for the analysis of panels, exomes, and genomes for hereditary diseases and oncology. We offer a comprehensive, secure platform and partner with clinical labs to help them interpret variants faster, integrate with EMRs, and ultimately sign out cases more efficiently. Fabric Genomics was founded by scientists and industry pioneers in bioinformatics, large-scale genomics, and clinical genetics, and is headquartered in Oakland, California. To learn more, visit www.fabricgenomics.com, and follow us on Twitter and LinkedIn.

Contacts

Fabric Genomics
Vanessa Sawyer
Director of Global Marketing
vsawyer@fabricgenomics.com